Soybean oil enriched with stearidonic acid (SDA) can raise levels of eicosapentaenoic acid (EPA) in the blood, according to research published in the American Journal of Clinical Nutrition.
Soybean oil enriched with stearidonic acid (SDA) can raise levels of eicosapentaenoic acid (EPA) in the blood, according to research published in the American Journal of Clinical Nutrition.
Funded by Monsanto Co. (St. Louis) and Solae Co. (St. Louis), the study tested the effects of genetically-modified, SDA-enriched soybean oil on omega-3 blood levels in 52 overweight subjects over 12 weeks. In the randomized, placebo-controlled, double-blind study, subjects were assigned to one of three treatments, daily: 1 g of encapsulated soybean oil and 14.7 g liquid soybean oil mixed into food (control group), 1 g of encapsulated EPA and 14.7 g of liquid soybean oil (EPA group), or 1 g encapsulated soybean oil and 14.7 g liquid SDA-enriched soybean oil. The SDA-enriched soybean oil contained 4.2 g of SDA.
At baseline, mean omega-3 indexes were similar for the control, EPA, and SDA groups; but, after 12 weeks, indexes shifted in favor of the omega-3 groups with mean indexes of 4.15, 4.84, and 4.69, respectively. No adverse health effects were related to SDA.
Results of the study led researchers to conclude that the SDA-enriched soybean oil is 'a sustainable approach to increasing tissue concentration of long-chain polyunsaturated omega-3 fatty acids.'ÃÂ
To read the study abstract, click here.
Recent animal study finds that Lysoveta may help reduce neonatal brain injury
July 17th 2024A recent animal study found that lysophosphatidylcholine (LPC)-bound omega-3 long-chain polyunsaturated fatty acids (LCPUFAs), marketed as Lysoveta by Aker BioMarine, protected against neonatal hypoxic-ischemic (HI) brain injury in mice.
Krill oil supplementation raises Omega-3 Index of Lupus patients in recent study
July 16th 2024The study was conducted at 20 research centers in the United States by Aker BioMarine and the Lupus Clinical Investigators Network with oversight by Lupus Therapeutics, the clinical research affiliate of the Lupus Research Alliance.
Meta-analysis does not find increased risk of bleeding events from omega-3 PUFA consumption
July 8th 2024Researchers reviewed 11 studies and found that there was no difference in the incidence of bleeding events between patients receiving omega-3 PUFAs and those not receiving them. High dose EPA consumption was associated with an elevated but modest risk.
Recent review states that pentadecanoic acid may support cellular stability for better longevity
June 25th 2024According to the paper’s author, Stephanie Venn-Watson, DVM, MPH, deficiency in pentadecanoic acid of ≤0.2% total circulating fatty acids increases the risk of ferroptosis, which a type of cell death cause by the peroxidation of fragile fatty acids in cell membranes that combines with iron thus increasing reactive oxygen species, and disabling mitochondria.